Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients

Tsu Yi Chao, Ching Liang Ho, Su Huei Lee, Mary Mei Ju Chen, Anthony Janckila, Lung T. Yam

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Diagnosis and follow-up of bone metastases in breast cancer patients usually rely on symptoms and imaging studies. Tartrate-resistant acid phosphatase 5b (TRACP 5b) is a specific marker of osteoclasts and is herein proposed as a marker of bone metastasis in breast cancer patients. An immunoassay using a monoclonal antibody, 14G6, was used to measure the activity of serum TRACP 5b at pH 6.1 in 30 early breast cancer patients without bone metastasis and in 30 aged-matched breast cancer patients with bone metastasis. Another 60 normal volunteers were recruited as controls. Bone alkaline phosphatase (BAP), a traditional marker of bone turnover, was also measured in selected cases. The overall mean TRACP 5b activity in normal women was 2.83 ± 1.1 U/l, and it increased with age. The mean TRACP 5b activity in early breast cancer patients did not differ from that of the normal group (2.93 ± 0.64 vs. 2.83 ± 1.1 U/l; p = 0.66), whereas it was significantly higher in breast cancer patients with bone metastasis (5.42 ± 2.5 vs. 2.83 ± 1.1 U/l; p <0.0001). BAP activity was significantly higher in breast cancer patients with bone metastasis than in early breast cancer patients (p = 0.004). Serum TRACP 5b activity correlated well with BAP activity in breast cancer patients with bone metastasis (p <0.0001), but not in normal individuals or in patients without bone metastasis. TRACP 5b activity can be considered a surrogate indicator of bone metastasis in breast cancer patients.

Original languageEnglish
Pages (from-to)511-516
Number of pages6
JournalJournal of Biomedical Science
Volume11
Issue number4
DOIs
Publication statusPublished - 2004
Externally publishedYes

Fingerprint

Acid Phosphatase
Bone
Biomarkers
Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Alkaline Phosphatase
Tartrate-Resistant Acid Phosphatase
tartaric acid
Bone Remodeling
Osteoclasts
Serum
Immunoassay
Healthy Volunteers
Monoclonal Antibodies

Keywords

  • Bone metastasis
  • Breast cancer
  • Prognostic marker
  • Tracp activity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. / Chao, Tsu Yi; Ho, Ching Liang; Lee, Su Huei; Chen, Mary Mei Ju; Janckila, Anthony; Yam, Lung T.

In: Journal of Biomedical Science, Vol. 11, No. 4, 2004, p. 511-516.

Research output: Contribution to journalArticle

Chao, Tsu Yi ; Ho, Ching Liang ; Lee, Su Huei ; Chen, Mary Mei Ju ; Janckila, Anthony ; Yam, Lung T. / Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. In: Journal of Biomedical Science. 2004 ; Vol. 11, No. 4. pp. 511-516.
@article{5f5f169deac949a7af415f09d34934cc,
title = "Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients",
abstract = "Diagnosis and follow-up of bone metastases in breast cancer patients usually rely on symptoms and imaging studies. Tartrate-resistant acid phosphatase 5b (TRACP 5b) is a specific marker of osteoclasts and is herein proposed as a marker of bone metastasis in breast cancer patients. An immunoassay using a monoclonal antibody, 14G6, was used to measure the activity of serum TRACP 5b at pH 6.1 in 30 early breast cancer patients without bone metastasis and in 30 aged-matched breast cancer patients with bone metastasis. Another 60 normal volunteers were recruited as controls. Bone alkaline phosphatase (BAP), a traditional marker of bone turnover, was also measured in selected cases. The overall mean TRACP 5b activity in normal women was 2.83 ± 1.1 U/l, and it increased with age. The mean TRACP 5b activity in early breast cancer patients did not differ from that of the normal group (2.93 ± 0.64 vs. 2.83 ± 1.1 U/l; p = 0.66), whereas it was significantly higher in breast cancer patients with bone metastasis (5.42 ± 2.5 vs. 2.83 ± 1.1 U/l; p <0.0001). BAP activity was significantly higher in breast cancer patients with bone metastasis than in early breast cancer patients (p = 0.004). Serum TRACP 5b activity correlated well with BAP activity in breast cancer patients with bone metastasis (p <0.0001), but not in normal individuals or in patients without bone metastasis. TRACP 5b activity can be considered a surrogate indicator of bone metastasis in breast cancer patients.",
keywords = "Bone metastasis, Breast cancer, Prognostic marker, Tracp activity",
author = "Chao, {Tsu Yi} and Ho, {Ching Liang} and Lee, {Su Huei} and Chen, {Mary Mei Ju} and Anthony Janckila and Yam, {Lung T.}",
year = "2004",
doi = "10.1159/000077901",
language = "English",
volume = "11",
pages = "511--516",
journal = "Journal of Biomedical Science",
issn = "1021-7770",
publisher = "BioMed Central",
number = "4",

}

TY - JOUR

T1 - Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients

AU - Chao, Tsu Yi

AU - Ho, Ching Liang

AU - Lee, Su Huei

AU - Chen, Mary Mei Ju

AU - Janckila, Anthony

AU - Yam, Lung T.

PY - 2004

Y1 - 2004

N2 - Diagnosis and follow-up of bone metastases in breast cancer patients usually rely on symptoms and imaging studies. Tartrate-resistant acid phosphatase 5b (TRACP 5b) is a specific marker of osteoclasts and is herein proposed as a marker of bone metastasis in breast cancer patients. An immunoassay using a monoclonal antibody, 14G6, was used to measure the activity of serum TRACP 5b at pH 6.1 in 30 early breast cancer patients without bone metastasis and in 30 aged-matched breast cancer patients with bone metastasis. Another 60 normal volunteers were recruited as controls. Bone alkaline phosphatase (BAP), a traditional marker of bone turnover, was also measured in selected cases. The overall mean TRACP 5b activity in normal women was 2.83 ± 1.1 U/l, and it increased with age. The mean TRACP 5b activity in early breast cancer patients did not differ from that of the normal group (2.93 ± 0.64 vs. 2.83 ± 1.1 U/l; p = 0.66), whereas it was significantly higher in breast cancer patients with bone metastasis (5.42 ± 2.5 vs. 2.83 ± 1.1 U/l; p <0.0001). BAP activity was significantly higher in breast cancer patients with bone metastasis than in early breast cancer patients (p = 0.004). Serum TRACP 5b activity correlated well with BAP activity in breast cancer patients with bone metastasis (p <0.0001), but not in normal individuals or in patients without bone metastasis. TRACP 5b activity can be considered a surrogate indicator of bone metastasis in breast cancer patients.

AB - Diagnosis and follow-up of bone metastases in breast cancer patients usually rely on symptoms and imaging studies. Tartrate-resistant acid phosphatase 5b (TRACP 5b) is a specific marker of osteoclasts and is herein proposed as a marker of bone metastasis in breast cancer patients. An immunoassay using a monoclonal antibody, 14G6, was used to measure the activity of serum TRACP 5b at pH 6.1 in 30 early breast cancer patients without bone metastasis and in 30 aged-matched breast cancer patients with bone metastasis. Another 60 normal volunteers were recruited as controls. Bone alkaline phosphatase (BAP), a traditional marker of bone turnover, was also measured in selected cases. The overall mean TRACP 5b activity in normal women was 2.83 ± 1.1 U/l, and it increased with age. The mean TRACP 5b activity in early breast cancer patients did not differ from that of the normal group (2.93 ± 0.64 vs. 2.83 ± 1.1 U/l; p = 0.66), whereas it was significantly higher in breast cancer patients with bone metastasis (5.42 ± 2.5 vs. 2.83 ± 1.1 U/l; p <0.0001). BAP activity was significantly higher in breast cancer patients with bone metastasis than in early breast cancer patients (p = 0.004). Serum TRACP 5b activity correlated well with BAP activity in breast cancer patients with bone metastasis (p <0.0001), but not in normal individuals or in patients without bone metastasis. TRACP 5b activity can be considered a surrogate indicator of bone metastasis in breast cancer patients.

KW - Bone metastasis

KW - Breast cancer

KW - Prognostic marker

KW - Tracp activity

UR - http://www.scopus.com/inward/record.url?scp=2642562768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642562768&partnerID=8YFLogxK

U2 - 10.1159/000077901

DO - 10.1159/000077901

M3 - Article

VL - 11

SP - 511

EP - 516

JO - Journal of Biomedical Science

JF - Journal of Biomedical Science

SN - 1021-7770

IS - 4

ER -